ITGAM and neoplasm: A comparison of the ratios of CD11b+ myeloid cells to CD3+ T cells indicated that SAR131675 treatment significantly decreased this ratio in both liver and tumor (Table 1), indicating a shift in the balance of immune response, favoring an anti-tumor effect.